Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

  1. Camidge, D.R.
  2. Kim, H.R.
  3. Ahn, M.-J.
  4. Yang, J.C.H.
  5. Han, J.-Y.
  6. Hochmair, M.J.
  7. Lee, K.H.
  8. Delmonte, A.
  9. Garcia Campelo, M.R.
  10. Kim, D.-W.
  11. Griesinger, F.
  12. Felip, E.
  13. Califano, R.
  14. Spira, A.I.
  15. Gettinger, S.N.
  16. Tiseo, M.
  17. Lin, H.M.
  18. Liu, Y.
  19. Vranceanu, F.
  20. Niu, H.
  21. Zhang, P.
  22. Popat, S.
Journal:
Journal of Thoracic Oncology

ISSN: 1556-1380 1556-0864

Year of publication: 2021

Volume: 16

Issue: 12

Pages: 2091-2108

Type: Article

DOI: 10.1016/J.JTHO.2021.07.035 GOOGLE SCHOLAR lock_openOpen access editor